Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dunn

Showing results (21-30 of 149) with videos related to

Pageof 15
Sort By:
The Clinical Teacher|December 8, 2010
Family residents' interventions during in-hospital callFrançois Lehmann, David Dunn, Ariane Murray, et al.
Health Promotion Practice|December 3, 2004
Assessment of the training needs of Kentucky public health educatorsLisa L Lindley, Richard W Wilson, J David Dunn
The Journal of Infectious Diseases|May 10, 2002
Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcomeJohn Frater, David Dunn, Jonathan N Weber, et al.
Antiviral Therapy|May 29, 2008
The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trialAlejandro Arenas-Pinto, Krishnan Bhaskaran, David Dunn, et al.
Journal of Virology|January 23, 2009
Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individualsStéphane Hué, Robert J Gifford, David Dunn, et al.
Annals of the New York Academy of Sciences|January 6, 2006
Adolescents with disruptive behavior disorder investigated using an optimized MR diffusion tensor imaging protocolTie-Qiang Li, Vincent P Mathews, Yang Wang, et al.
Journal of the International AIDS Society|November 14, 2014
Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patientsLars Oddershede, Simon Walker, Nicholas Paton, et al.
Clinical Trials (London, England)|January 23, 2025
Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trialSheila Kansiime, Christian Holm Hansen, Eugene Ruzagira, et al.
Clinical Neuropharmacology|May 8, 2012
Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioningLinda Wietecha, Joel Young, Dustin Ruff, et al.
The Journal of Infectious Diseases|August 19, 2005
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United KingdomDeenan Pillay, Hannah Green, Ryanne Matthias, et al.
Pageof 15

Showing results (21-30 of 149) with videos related to

Sort By:
Pageof 15
The Clinical Teacher|December 8, 2010
Family residents' interventions during in-hospital callFrançois Lehmann, David Dunn, Ariane Murray, et al.
Health Promotion Practice|December 3, 2004
Assessment of the training needs of Kentucky public health educatorsLisa L Lindley, Richard W Wilson, J David Dunn
The Journal of Infectious Diseases|May 10, 2002
Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcomeJohn Frater, David Dunn, Jonathan N Weber, et al.
Antiviral Therapy|May 29, 2008
The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trialAlejandro Arenas-Pinto, Krishnan Bhaskaran, David Dunn, et al.
Journal of Virology|January 23, 2009
Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individualsStéphane Hué, Robert J Gifford, David Dunn, et al.
Annals of the New York Academy of Sciences|January 6, 2006
Adolescents with disruptive behavior disorder investigated using an optimized MR diffusion tensor imaging protocolTie-Qiang Li, Vincent P Mathews, Yang Wang, et al.
Journal of the International AIDS Society|November 14, 2014
Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patientsLars Oddershede, Simon Walker, Nicholas Paton, et al.
Clinical Trials (London, England)|January 23, 2025
Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trialSheila Kansiime, Christian Holm Hansen, Eugene Ruzagira, et al.
Clinical Neuropharmacology|May 8, 2012
Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioningLinda Wietecha, Joel Young, Dustin Ruff, et al.
The Journal of Infectious Diseases|August 19, 2005
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United KingdomDeenan Pillay, Hannah Green, Ryanne Matthias, et al.
Pageof 15